Ferric Sulfate in Pediatric Dentistry: Is It the Right Choice for Pulpotomies?
"Navigating the evidence-based landscape of pulpotomy medicaments to determine the efficacy of ferric sulfate in primary molars."
Pulpotomy is a vital dental procedure involving the removal of inflamed coronal pulp while preserving the healthy radicular pulp tissue in primary teeth. This intervention aims to maintain tooth vitality and structural integrity, which is crucial for proper chewing, speech development, and maintaining space for permanent teeth.
The ideal material for pulpotomy should preserve radicular pulp vitality within an odontoblast-lined dentine chamber. For decades, formocresol (FC) was favored for its ease of use and high success rates. However, concerns about its potential carcinogenicity and mutagenicity have prompted the search for safer alternatives. This has led to the exploration of materials like calcium hydroxide, calcium-enriched mixture (CEM) cement, electro-surgery, and, increasingly, ferric sulfate (FS).
Ferric sulfate has gained traction as a pulpotomy medicament. This article examines the evidence-based efficacy of FS compared to other pulpotomy treatments in primary molars. By evaluating existing research, we aim to provide clarity on whether FS stands as a reliable option in pediatric dentistry.
Pulpotomy Methods and Their Limitations
Pulpotomy is a vital pulp treatment frequently used in primary molars to preserve pulp vitality and function until the teeth exfoliate. A systematic review evaluated the available evidence on ferric sulfate (FS) compared with other pulpotomy medicaments, using studies identified through five databases. The sources note that no pulp medicament has all the features of an ideal pulpotomy material. A separate retrospective study compared radiographic success for sodium hypochlorite and FS in primary molars.
Ferric Sulfate: How Effective Is It?
Ferric sulfate (FS), known chemically as Fe2(SO4)3, typically used as a 15.5% solution, functions as a coagulative and hemostatic agent. When FS comes into contact with blood, it forms a ferric ion-protein complex, effectively sealing damaged blood vessels and creating hemostasis. This complex acts as a physical barrier, preventing further blood clot formation. Unlike some alternatives, FS is believed to have minimal devitalizing effects on pulp tissue.
- Comprehensive Search: Included PubMed, Ovid®, EBSCOhost, Cochrane Library, and ProQuest databases.
- Quality Assessment: Studies were graded based on pre-defined criteria by two independent researchers, ensuring reliability.
- Data Analysis: Kappa statistics were used to measure inter-examiner reliability.
Evidence from Recent Reviews
An umbrella review reported that one low-quality systematic review found a high success rate for ferric sulfate (FS), but the underlying studies provided limited high-quality evidence. A network meta-analysis included randomized controlled trials of pulpotomy medicaments including ferric sulfate, formocresol, sodium hypochlorite, calcium hydroxide, MTA, Biodentine, and laser. Eligible studies involved vital primary molars with carious pulp exposure, used zinc oxide-eugenol or reinforced zinc oxide-eugenol as an immediate restoration, and amalgam or a stainless steel crown as the final restoration. Clinical and radiographic success at 6 and 12 months were the stated outcomes, with at least 6 months of follow-up required.
Comparisons and Evidence Limits
A study of 45 primary molars compared clinical and radiographic success for diode laser, electrosurgical, and ferric sulfate pulpotomy over 9 months, noting that available pulpotomy materials and techniques have advantages and disadvantages. A separate systematic review and meta-analysis set out to assess success rates for primary molar pulpotomy using ferric sulfate (FS) or mineral trioxide aggregate (MTA). The supplied information gives the aims and study scope, but does not report comparative results, so it does not establish which approach was more successful.
Ferric Sulfate Compared with Formocresol
A review comparing formocresol and ferric sulfate in pulpotomized primary molars concluded that the treatments had similar clinical and radiographic success rates. The review also cautioned that this conclusion's reliability was unclear because most included studies were of poor or unknown quality. A 2024 study described formocresol as the long-standing gold standard and ferric sulfate as an emerging alternative, and set out to compare their clinical effectiveness. Its supplied summary does not provide the study's results.
The Verdict: Is Ferric Sulfate Ready for Prime Time?
Based on the findings, current evidence does not strongly support the widespread application of FS as a pulpotomy medicament in primary molars within the existing English literature. The limited number of high-quality studies suggests that while FS shows promise, more rigorous research is needed.
Safety and Longer-Term Evidence
A ScienceDirect overview reports that long-term prospective randomized clinical trials with inferential statistical analysis found ferric sulfate equivalent to formocresol pulpotomy and described a wider margin of safety. It also reports a local but reversible inflammatory response in oral soft tissues. A separate source describes a completed 3-year comparative study of ferric sulfate and diluted formocresol in pulpotomized primary teeth. The supplied description does not state that study's results.
To solidify FS’s position as an effective alternative, future studies should prioritize: Randomised clinical trials with larger sample sizes, Long-term follow-up periods to assess sustained success and Standardised assessment criteria for clinical and radiographic outcomes.
In conclusion, while ferric sulfate presents a potential option for pulpotomies in primary molars, dental professionals should remain cautious. High-quality research is crucial to fully understand its efficacy and long-term outcomes compared to traditional and newer medicaments. Until more robust evidence emerges, a balanced approach considering both the potential benefits and limitations of FS is warranted.